ProfileGDS5678 / 1417128_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 90% 91% 91% 89% 89% 91% 92% 89% 86% 89% 90% 89% 90% 88% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.2514990
GSM967853U87-EV human glioblastoma xenograft - Control 27.5169591
GSM967854U87-EV human glioblastoma xenograft - Control 37.3738991
GSM967855U87-EV human glioblastoma xenograft - Control 47.1296989
GSM967856U87-EV human glioblastoma xenograft - Control 57.0497389
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.1288191
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.4640492
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.9961189
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.4473386
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.0016889
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.092990
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.1387889
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.2637590
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.9145688